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Abstract
Murine noroviruses have emerged as a valuable tool for investigating the molecular basis of infection and pathogenesis of
the closely related human noroviruses, which are the major cause of non-bacterial gastroenteritis. The replication of
noroviruses relies on the proteolytic processing of a large polyprotein precursor into six non-structural proteins (NS1–2, NS3,
NS4, NS5, NS6
pro, NS7
pol) by the virally-encoded NS6 protease. We report here the crystal structure of MNV NS6
pro, which
has been determined to a resolution of 1.6 A ˚. Adventitiously, the crystal contacts are mediated in part by the binding of the
C-terminus of NS6
pro within the peptide-binding cleft of a neighbouring molecule. This insertion occurs for both molecules
in the asymmetric unit of the crystal in a manner that is consistent with physiologically-relevant binding, thereby providing
two independent views of a protease-peptide complex. Since the NS6
pro C-terminus is formed in vivo by NS6
pro processing,
these crystal contacts replicate the protease-product complex that is formed immediately following cleavage of the peptide
bond at the NS6-NS7 junction. The observed mode of binding of the C-terminal product peptide yields new insights into the
structural basis of NS6
pro specificity.
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Introduction
Noroviruses are members of the calicivirus family of positive
sense RNA viruses. In humans noroviruses cause rapid onset
diarrhoea and vomiting, a condition often referred to as gastric flu.
Noroviral gastroenteritis is estimated to affect 21 million people
annually in the United States [1], and to be responsible for up to
200,000 deaths a year in developing nations [2]. Despite the
obvious medical importance of norovirus infections, there are still
no vaccines or antiviral treatments.
One of the reasons for the slow progress in drug and vaccine
development has been the lack of cell culture and small animal
model systems for studying the molecular mechanisms and
pathology of noroviral gastroenteritis. These limitations have been
partly overcome thanks to the relatively recent development of cell
culture [3], and reverse genetics techniques for murine norovirus
(MNV) [4–6]. MNV is closely related to human noroviruses and
some strains are known to cause gastroenteritis in STAT1 (2/2)
mice [7]. The virus has therefore emerged as an important
surrogate model for studying human norovirus infections at the
molecular level.
The Norovirus genome is approximately 7.5 kb in length and
encodes three open reading frames (ORFs). ORF2 and ORF3
encode the major and minor capsid proteins respectively [8,9],
while ORF1 encodes a non-structural polyprotein that is cleaved
into functional units by the viral protease (NS6
pro) [10–14]. There
are five cleavage junctions in the norovirus polyprotein, so
processing ultimately releases six cleavage products, all of which
play essential roles in the intracellular replication cycle of the virus
[12,14]. These include NS1–2, a protein that disrupts cellular
trafficking [15]; NS3, an ATPase and putative helicase [16]; NS4,
a protein that also interferes with cellular protein trafficking within
infected cells [17]; NS5, also known as VPg, the genome-linked
protein that has key roles in the translation and replication of the
viral RNA genome [18]; NS6
pro, the viral protease itself [19]; and
NS7
pol, an RNA-dependent RNA polymerase [20].
Although there is some variation in the sequence of the five
cleavage sites recognised by norovirus NS6
pro, common features
are identifiable. The amino acids on the N-terminal side of the
cleaved peptide bond (the P1 position in the nomenclature of
Schechter and Berger [21]) are typically glutamine or glutamic
acid, while the P19 amino acids on the C-terminal side is usually
glycine or alanine; the residues at the P2 and P4 positions tend to
be large and hydrophobic in nature [12,14].
X-ray crystallographic analysis of the NS6 protease from three
different strains of human norovirus [19,22,23] has revealed the
protein to be a cysteine protease with a chymotrypsin-like fold,
similar to that of the 3C proteases from picornaviruses [24,25].
The NS6
pro fold is composed of two b-barrel domains tightly
packed against each other; the interface between these two
domains forms the peptide-binding cleft at the centre of which is
the protease active site, a catalytic triad consisting of cysteine,
histidine and aspartic or glutamic acid [22]. While the catalytic
mechanism of NS6
pro and 3C
pro enzymes has not been fully
defined, it has been shown to involve all three amino acids of the
triad [22,26–28] and is therefore likely to resemble the mechanism
of the serine proteases.
In one of these crystallographic studies, the structure of human
norovirus NS6
pro was determined in complex with a peptide-like
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(positions P5 to P1) was covalently attached – by the action of a C-
terminal Michael acceptor – to the cysteine nucleophile in the
active site of the enzyme. Although the mode of binding was
similar to that observed for other chymotrypsin-like proteases, the
chemical modifications of the peptide that were made to add the
Michael acceptor to the inhibitor resulted in steric clashes that
distorted the protease active site. In this report we extend the
structural work on noroviral proteases by describing the X-ray
structure of full-length MNV NS6
pro. Fortuitously the structure
has been solved in a crystal form in which the C-terminus of one
protease extends into the active site of another. This provides new
insights into peptide recognition by MNV NS6
pro.
Results and Discussion
To prevent autolysis of the protease in the high concentrations
used for crystallisation trials MNV NS6
pro was inactivated by
mutation of the active site nucleophile to alanine (C139A). This
mutant protease was expressed in E. coli and purified using affinity
and size exclusion chromatography as described in the Materials
and Methods. The protein crystallised by hanging drop vapour
diffusion in 20% w/v PEG 3350, 0.2 M KSCN, 0.1 M Bis-Tris
propane pH 7.5 to yield crystals that belong to space-group C2221
and have two molecules in the asymmetric unit. They diffracted
X-rays to 1.6 A ˚ resolution, producing an electron density map of
extremely good quality for residues 1–123 and 132–183 in both
molecules of the asymmetric unit. However, electron density for
the solvent-exposed loop formed by residues 124–131 was very
weak, presumably due to disorder, and so was not included in the
NS6
pro model. The evident flexibility of this loop is consistent with
previous crystallographic analyses of human norovirus NS6
proteases which found the loop to be either disordered, as in the
Norwalk virus NS6
pro structure [22], or to adopt very dissimilar
conformations, as in the structures of Chiba virus (CV) and
Southampton virus (SV) NS6
pro [19,23]. The final refined crystal
structure of MNV NS6
pro has an Rfree value of 20.8% and very
good stereochemistry (full data collection and refinement statistics
are summarised in Table 1).
The overall structure of the MNV NS6 protease is nearly
identical to Norwalk virus, SV and CV NS6
pro (Fig. 1), which
comes as no surprise given the high degree of amino acid identity
(,60%) between these proteins. As described previously, the
structure is an abbreviated form of the chymotrypsin-like 3C
proteases from picornaviruses [19,22], which comprise two b-
barrel domains. Specifically, in norovirus NS6 proteases, the b-
strands on one side of the N-terminal b-barrel are so much shorter
that the domain is better considered as a single b-sheet decorated
by loops (Fig. 1A). The active site triad of H30, D54, and C139
(A139 in our mutated protein) is located in the centre of the
peptide-binding cleft formed at the interface of these two domains.
In the norovirus NS6
pro crystal structures published to date it
has already been observed that, whereas the N-terminal helix
found in picornavirus 3C proteases is retained in NS6
pro, the C-
terminal helix in 3C
pro is not found in the norovirus proteases
[19,22,23]. Instead the C-terminal polypeptide of NS6
pro appears
to be largely unstructured; it is either disordered or adopts very
different conformations that appear to be determined by crystal
contacts (Fig. 1B). Strikingly, in our structure the flexibility of the
C-terminal polypeptide has actually allowed it to associate with the
peptide-binding sites of a neighbouring molecule in the crystal –
a happy accident that has revealed the structure of an MNV
NS6
pro-peptide complex (Fig. 2A). The interaction occurs for both
molecules of the asymmetric unit, although in each case the C-
terminus extends from the body of the protease in a different
direction towards its neighbour (Fig. 2B). For chain A, the
interaction is symmetric: it donates its C-terminus to a neighbour-
ing A-chain that is related by crystallographic two-fold symmetry
and binds the C-terminus received from this molecule. This pair of
molecules thus forms a closed complex. In contrast, chain B
donates its C-terminus to a neighbouring B-chain but binds the C-
terminus of a third molecule (also a B-chain). Despite these
differences, the interactions made with the neighbouring protease
by the residues corresponding to the P4-P1 amino acids of the
donated C-terminus are in each case essentially identical (Fig. 2C).
Superposition of the crystal structure of Southampton Virus
NS6
pro with a covalently-attached peptide-like inhibitor shows that
the positions of the P4-P1 amino acids are very similar to our
MNV NS6
pro ‘co-crystal’ structure [23] (Fig. 3A, C). The positions
of the P4-P1 amino acids observed in the peptide-binding site of
MNV NS6
pro are also very similar to the equivalent residues in the
co-crystal structure of FMDV 3C
pro:peptide complex [29] (not
shown). This indicates that, although the formation of an MNV
protease-peptide complex is an accident of crystallisation, crystal-
packing constraints do not prevent the C-terminal residues from
adopting a physiologically-relevant conformation in the binding
site of a neighbouring molecule.
The adventitious insertion of the NS6
pro C-terminus into the
peptide-binding cleft of neighbouring proteases in our crystals has
Table 1. Crystallographic data collection and model
refinement statistics for MNV NS6
pro.
Data collection
Space-group C2221
a, b, c (A ˚) 50.9, 70.4, 192.3
a, b, c (u) a=b=c=90
Resolution range (A ˚) 48.03–1.58 (1.62–1.58)
No. of independent reflections 44,988
Multiplicity
1 12.4 (8.4)
Completeness (%) 94.2 (65.3)
I/sI 29.8 (3.2)
Rmerge (%)
2 4.0 (55.0)
Model refinement
No. of Non-hydrogen atoms/waters 2611/290
Rwork (%)
3 18.4 (26.6)
Rfree (%)
4 20.8 (30.3)
Average B-factor 32.1
RMS deviations – Bonds (A ˚)
5 0.006
RMS deviations – Angles (u) 0.980
Ramachandran plot
Favoured 98.3
Allowed 1.7
PDB Accession Code 4ash
1Values for highest resolution shell given in parentheses.
2Rmerge =100 6Shkl|Ij(hkl) 2, Ij(hkl).|/ShklSjI(hkl), where Ij(hkl) and ,Ij(hkl).
are the intensity of measurement j and the mean intensity for the reflection
with indices hkl, respectively.
3Rwork =100 6Shkl||Fobs| 2 |Fcalc||/Shkl|Fobs|.
4Rfree is the Rmodel calculated using a randomly selected 5% sample of reflection
data that were omitted from the refinement.
5RMS, root-mean-square; deviations are from the ideal geometry defined by the
Engh and Huber parameters [45].
doi:10.1371/journal.pone.0038723.t001
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the protease-product complex of MNV NS6
pro that forms
following cleavage of the NS6-NS7 junction in the viral
polyprotein. All of the amino acids on the P-side of the cleavage
junction are visible in the electron density map and are included in
the model. The primary contacts with the protease are made by
the carboxylate group of P1-Gln and side-chains of P1-Gln, P2-
Phe and P4-Leu. Although the P5 and P6 amino acids make some
contact with the protease, their positions differ for molecules A and
B in the asymmetric unit. These differences are likely to be due to
differences in crystal packing, so our structure does not give a clear
indication that they are important for peptide recognition.
The co-crystal structure of SV NS6
pro with a P5–P1 (EFQLQ)
peptide-based inhibitor covalently attached to the active site
nucleophile [23] reveals a conformation for the bound peptide
over the region P1–P4 that is very similar to the MNV NS6
pro-
peptide complex, although there are some differences in detail
caused by sequence variation and a notable structural alteration at
the active site due to the chemical modification of the peptide
inhibitor needed to introduce the reactive Michaels acceptor (see
below).
P1 residue recognition by MNV NS6
pro is mediated primarily
by a specificity triad of residues composed of H157, T134 and
Y143. The side-chain carbonyl of the P1-Gln in the peptide
(Q183) forms hydrogen bonds with the imidazole ring of H157
and the T134 hydroxyl group (Fig. 3A); in turn, H157 is stabilised
by a hydrogen bond from the hydroxyl group of Y143. This mode
of interaction could be replicated by a P1-Glu residue and
accounts for the ability of NS6
pro to cleave substrates with P1-Gln
or P1-Glu. The specificity triad, which is also found in human
norovirus NS6
pro structures, is also conserved in picornaviral
3C
pro enzymes from poliovirus, human rhinovirus, coxsackie A
virus (CAV) and FMDV [24,30–32] and explains the ability to
cleave after P1-Gln or P1-Glu, although only FMDV is exceptional
in not having a strong preference for P1-Gln [29,33].
The P1-Gln of the peptide ‘product’ is also stabilised by
interactions made by its carboxylate group with the main-chain
amides of G137 and A139 (the oxyanion hole), and with the e
amine group of H30 (Fig. 3A). An essentially identical set of
interactions was observed to stabilise the carboxylate group of the
P1 residue in the co-crystal structure of the picornavirus CAV
3C
pro in complex with a peptide corresponding to the N-terminal
half of the cleavage product [30] (Fig. 3F), and in the crystal
structure of the Tobacco Etch virus 3C-like NIa protease where, as
in our structure, the C-terminus of the protease is observed to be
bound in the active site (although in the case of NIa crystals it is
not known whether this is a cis or trans insertion) [34]. In contrast,
this mode of interaction did not occur in the complex of SV
NS6
pro with a peptide-like inhibitor because of the non-standard
nature of the C-terminus of the SV peptide [23]; in that case the
carboxylate group at the end of the peptide is separated from the
Ca of the P1 residue by an additional C–C bond, which has the
effect of distorting the geometry of the SV NS6
pro site (Fig. 3C). In
particular, the side chain of H30 in the catalytic triad of SV
NS6
pro is rotated out of the position needed for catalysis. In
contrast, the active site geometry observed in the MNV NS6
pro
structure is almost identical to that of the unliganded Norwalk
virus protease, albeit allowing for the fact that the general acid in
Norwalk virus NS6
pro catalytic triad is a Glu but an Asp in MNV
(Fig. 1A, B) [19,22].
The side-chain of F182 at the P2 in the MNV NS6
pro structure
is sandwiched between H30 and I109 at the entrance to the
hydrophobic S2 pocket (Fig 3A, B) but also contacts V114, V158,
A159 and D54. The largely apolar nature of the S2 pocket
accounts for the general selectivity for hydrophobic amino acids at
the P2 amino acid in norovirus cleavage junctions [14] (Fig. 4). An
exception to this is the NS4/NS5 junction of the MNV
polyprotein, which has a P2-Ser. It seems unlikely that at the
side-chain hydroxyl of this amino acid could interact specifically
with the S2 pocket, suggesting that the NS4/NS5 junction may be
a sub-optimal substrate for the protease. Intriguingly, the S2
pocket is more enclosed in human norovirus NS6
pro structures
because the Q110-G111-R112 sequence at the top of the loop that
forms one flank of the pocket is replaced in MNV NS6
pro by the
G110-S111-A112 sequence, which has much smaller amino acids
(Fig. 3A–D).
Figure 1. Structural comparison of the MNV NS6 protease with human norovirus NS6
pro and foot-and-mouth disease virus 3C
pro. (A)
Cartoon representation of the MNV NS6
pro structure. The N and C-terminal domains are coloured green and orange respectively. The side-chains of
the amino acids that make up the catalytic triad, A139 (mutated from Cys), H30 and D54, are shown as sticks. A disordered loop formed by residues
124–130 (residues 124–131 in chain B) is indicated as a dashed line. The peptide bound to NS6
pro is not shown in this representation. (B) Overlay of
HuNV NS6 protease structures from Chiba (PDB-ID: 1WQS), Norwalk (PDB-ID: 2FYQ) and Southampton (PDB-ID: 2IPH) viruses [19,22,23]. Excluding the
variable C-termini, the root mean square deviations of the backbone atoms of Chiba, Norwalk and Southampton virus NS6
pro from MNV NS6
pro are
0.62, 0.43 and 0.41 respectively. The disordered C-terminus of the Chibavirus protease is shown as a dashed line. (C) Structure of FMDV 3C
pro (PDB-ID:
2J92) [26], coloured as in panel (A).
doi:10.1371/journal.pone.0038723.g001
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pro-peptide
complex makes no specific interactions with the protease, though
it’s position is stabilised by b-strand-like interactions between its
main-chain amide and carbonyl groups and the main-chain
surrounding A160 (Fig. 3A), a mode of binding that is common to
chymotrypsin-like proteases. The absence of any interaction with
the P3 side-chain explains the diversity of residues (Q|G|K|N|E)
observed at this position in MNV cleavage junctions [14], a feature
that is also shared by picornavirus 3C
pro cleavage junctions
[29,30].
In contrast, at the P4 position in the ‘peptide’ the side-chain of
L180 occupies the hydrophobic S4 specificity pocket, which is
made up of T166, T161, I109, A159, I168 and I107. This mode of
interaction is very similar to the binding of apolar P4 amino acids
observed in structures of SV NS6
pro [23] and picornaviral 3C
proteases [29,35], reflecting the general – but not universal –
conservation of hydrophobic functional groups at P4 in specific
substrates for these enzymes [36]. In MNV cleavage junctions
there is a strong preference for large hydrophobic residues at P4
(W|Y|I|F|L), all of which could be accommodated in the deep,
apolar S4 pocket.
Beyond the P4 position there appears to be little specific
interaction between the peptide and the protease. In MNV NS6
pro
the side chain of the P5 residue (A179) does not contact the
protease. This finding echoes the lack of observable contact
between FMDV 3C
pro and the P5 amino acid of its peptide
substrate [29]. Moreover, the high diversity of amino acid at P5 in
MNV cleavage junctions (E|D|W|K|A) is consistent with the
notion that this residue is not a determinant of specificity (Fig. 4).
Although the P5-Glu in the co-crystal structure of SV NS6
pro with
a peptide-like inhibitor was observed to interact with the main
chain amide of Q109 via a water molecule (Fig 3C), this could be
an artefact of crystallisation [23]. While it remains true that
efficient catalysis by NS6
pro requires substrates that have at least
five residues on the P-side of the scissile bond – since removal of
the P5 residue from a synthetic substrate for SV NS6
pro resulted in
a nine-fold decrease in the kcat/KM specificity constant [23] –
there is no evidence that residues beyond P4 contribute to
specificity.
It is of interest to note that, despite the observation in the crystal
structure of numerous specific contacts between the P4–P1
residues and the protease, comparative analysis of the proteolysis
of mutated NS6
pro cleavage sites in the polyprotein has tended to
suggest that there are relatively few strong determinants of
cleavage specificity [28,37]. Although these studies reported
tolerance of substitutions at positions P4, P2, P1 and P19, this
interpretation is based on analyses of self-processing of polyprotein
precursors at a single time point following translation in rabbit
reticulocyte lysates [28] or following over-expression in E. coli [37].
Such techniques are lacking in sensitivity. For example, our
previous work with FMDV 3C
pro showed that analysis of
polyprotein cleavage rates by over-expression in E. coli could not
distinguish from wild-type a mutant that in in vitro assays (using
purified protein and synthetic peptide substrates) had only 1% of
wild-type activity [26]. We suspect therefore that, consistent with
the crystal structure reported here (Fig. 3) and broad patterns of
Figure 2. Variations in the crystal packing of the MNV NS6
pro A
and B chains in the asymmetric unit. (A) Crystal packing of A and B
chains of MNV NS6
pro. The A and B chains of one asymmetric unit are
shown along with the neighbouring molecules (labelled A’ and B’) into
which they insert their C-termini. (B) This panel shows the same
molecules that are depicted in panel A (with the same colouring) but in
this case the A and B chains within the asymmetric unit are superposed;
this reveals the very different contacts that they make with their closest
neighbour in the crystal. (C) Here the A’ and B’ chains from panel A are
now superposed in order to show the similarity of the conformations of
the bound C-termini (shown as sticks) from the A and B chains
respectively. Colour-coding is the same as panel A.
doi:10.1371/journal.pone.0038723.g002
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pro does indeed discriminate
between amino acids at the P1, P2 and P4 positions. The
contribution to specificity of residues on the P9 side of the scissile
bond remains to be fully investigated.
In summary, crystallisation of MNV NS6
pro has provided an
unexpected insight into the nature of protease-peptide interactions
because of the insertion of the C-terminus of the protein (a product
of NS6
pro cleavage) into the peptide binding cleft of neighbouring
Figure 3. Comparative analysis of protease-peptide interactions for the P6–P1 residues in MNV and SV NS6
pro and CAV 3C
pro. The N-
terminal and C-terminal b-barrel domains of each protease are coloured green and orange respectively. (A) Binding of residues P5–P1 (C-terminus of
NS6
pro), shown as sticks colour-coded by atom type (Carbon – light-blue; Oxygen – red; Nitrogen – blue), within the peptide binding grove of MNV
NS6
pro. Selected side-chains from the protease are also shown as sticks. Hydrogen bonds and salt-bridges mentioned in the text are indicated by
black dashed lines; all such bonds shown are #3.1 A ˚. (B) Same view as in A but showing the surface of MNV NS6
pro. (C) Binding of residues P5–P1
from a peptide-like inhibitor to SV (a human norovirus) [23]. Water molecules involved in the protease-peptide interaction are shown as red spheres.
(D) Same view as in B but showing the surface of SV NS6
pro. (E) The refined s-weighted 2Fo-Fc map electron density (where Fo and Fc are the
observed and calculated structure factors respectively) for an A-chain C-terminal peptide, shown at 1.5 s. (F) The interaction between residues P6–P1
of a peptide ‘product’ and CAV 3C
pro [30].
doi:10.1371/journal.pone.0038723.g003
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a snapshot of the protease-product complex that forms immedi-
ately following resolution of the covalent intermediate that forms
during catalysis. The protease-peptide interactions revealed in this
structure provide a basis for the engineering of specific NS6
pro
inhibitors.
It has occurred to us that by extending the C-terminus of MNV
NS6
pro to incorporate the sequence of the NS6-NS7 cleavage
junction, or to modify the sequence to that of other cleavage
junctions, it may be possible to exploit the same crystal form to
obtain structure of NS6
pro-substrate complexes. This would permit
examination of protease-peptide interactions on the P9 side of the
cleavage junction and work towards this goal is now in progress in
our laboratory.
Materials and Methods
cDNA for MNV1 strain CW1 NS6
pro (a kind gift from Dr Ian
Goodfellow – GenBank accession number YP724460) was
amplified by PCR and ligated into the expression vector pETM11
[38], which contains a thrombin cleavable N-terminal 6x poly-
histidine tag. QuikChange mutagenesis (Stratagene) was used to
introduce a C139A mutation into NS6
pro to knock out the active
site nucleophile of the enzyme. The primers used in cloning and
mutagenesis are given in Table 2. The protein was expressed in
BL21 (DE3) pLysS Escherichia coli cells by induction with 1 mM
IPTG for 3 hours at 37uC. The protein was purified on TALON
resin (Clontech); the polyhistidine tag was removed by overnight
incubation using approximately 10 U of thrombin (Sigma-Aldrich)
per milligram of purified protein. The cleaved protein was further
purified by size exclusion chromatography using a Hi-Load 16/60
Superdex 75 column (GE healthcare). Peak fractions were
concentrated to 750 mM in 25 mM Tris.HCl, pH 8.0 containing
200 mM NaCl and 5 mM Dithiothreitol. The purified protein
contained 185 residues comprising a non-native GS sequence at
the N-terminus, followed by all 183 residues of MNV NS6
pro.
Crystals were obtained using the sitting drop vapour diffusion
method by mixing 2 mL of protein solution with 1 mL of reservoir
solution. This was allowed to equilibrate over 125 mL reservoir
solution at room temperature. The reservoir solution was
composed of 0.2 M KSCN, 0.1 M Bis-Tris propane pH 7.5,
20% w/v poly-ethylene glycol (PEG) 3350 (condition 64 in the
Qiagen PACT suite of crystallisation buffers). Crystals were
transferred into a cryobuffer containing 0.2 M KSCN, 0.1 M Bis-
Tris propane pH 7.5, 30% w/v PEG 3350 prior to freezing in
liquid nitrogen. (MNV NS6
pro crystals were also obtained in 30%
w/v PEG 4000, 0.2 M MgCl2, 0.1 M Tris.HCl pH 8.5; 10% w/v
PEG 8000, 8% w/v ethylene glycol, 0.1 M HEPES, pH 7.5; 20%
w/v PEG 3350, 0.2 M sodium iodide, 0.1 M Bis-Tris-propane
pH 6.5; and 20% w/v PEG 3350, 0.2 M sodium iodide, 0.1 M
Bis-Tris-propane pH 8.5, but have not been tested for diffraction.)
X-ray diffraction data were collected at the Diamond Light
Source on the I04-1 beamline (wavelength 0.917 A ˚) using
a PILATUS 2 M detector. Data were indexed and scaled using
the XDS software package [39] and phased by molecular
replacement with Phaser using a weighted ensemble of the three
known human norovirus protease structures as a search model
[19,22,23,40]. Refinement and model manipulation were per-
formed using PHENIX and Coot respectively [41,42]. Structure
validation was performed using MolProbity [43].
Acknowledgments
We thank Dr Ian Goodfellow for kindly providing cDNA for MNV1 strain
CW1. We are grateful to the staff of beam-line I04-1 at the Diamond Light
Source, Didcot, UK for assistance with X-ray data collection.
Author Contributions
Conceived and designed the experiments: ENL SC. Performed the
experiments: GB ENL. Analyzed the data: ENL GB SC. Contributed
reagents/materials/analysis tools: GB. Wrote the paper: ENL SC.
Figure 4. Sequence conservation of polyprotein junction in
MNV that are cleaved by NS6
pro. (A) The five cleavage junctions of
MNV CW1 polyprotein (NCBI accession number YP_720001) [14]. (B)
Weblogo of polyprotein cleavage junctions cleaved by MNV NS6
pro. This
Weblogo was generated using 39 MNV polyprotein sequences and the
Weblogo sequence logo generator [44]. The height of the letter in each
case is indicative of the degree of conservation. The Genbank accession
numbers of the other sequences used to prepare the alignment are
ABU55618, ABU55627, ABU55615, ABU55621, ABU55612, ABU55624,
AEE10026, ABU55600, AEY83582, AEE10023, ABU55606, AEE10020,
ABU55609, AEE10017, ABB02416, AEE10002, ACJ72215, AEE09999,
ABU55591, AEE10005, ABU55570, AEE10008, ABU55585, AEE10014,
ABU55579, AEE10011, ABU55576, ABU55597, ABU55573, ABU55603,
ABU55582, ABU55594, ABU55588, ABU55567, ACS70958, ACJ72218,
ABS29272, ABS29274.
doi:10.1371/journal.pone.0038723.g004
Table 2. Cloning and C139A mutagenic primers used in the
course of the study.
MNV VPg 1–183 F CATCATGGATCCGCCCCAGTCTCCATCTGG
MNV VPg 1–183 R CATCATAAGCTTACTGGAACTCCAGAGCCTC
C139A QuikChange F CTCGGGACCATCCCAGGCGACGCA
GGCTGTCCCTATGTTTATAAG
C139A QuikChange R CTTATAAACATAGGGACAGCCTGC
GTCGCCTGGGATGGTCCCGAG
Restriction sites used in cloning are underlined. Mutations introduced using
QuikChange mutagenesis are in boldface.
doi:10.1371/journal.pone.0038723.t002
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